Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07256236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256236.